

The Antimycotic Activity of Rosuvastatin

Zahraa S. Qasim

Department of Clinical Laboratory Science, College of Pharmacy, University of Mosul, Mosul, Iraq.

Corresponding author: pharm.zahraa@uomosul.edu.iq

This is an open access article under the CC BY 4.0 license (<http://creativecommons.org/licenses/by/4.0/>)

Received

13-8-2022

Accepted

13-10-2022

ABSTRACT

Background: The steady increase in microbial resistance is a global health problem as a result of uncontrolled use of antimicrobial drugs, In order to overcome the challenge, there is a continuous need to search for new antimicrobials by either investigate novel compounds or repurposing drugs i.e. identifying new clinical use for existing approved agent thus saving time and cost required to develop a new antimicrobial therapy.

Aim: This study aimed to assess the *in vitro* antimycotic activity of different concentrations of rosuvastatin against 4 different fungi isolated from patients with malignancies 1 mold of genus *Aspergillus*, of 3 species (*A. flavus*, *A. niger*, and *A. fumigatus*) and 3 yeast of genus *Candida* of 2 species (*C. albicans*, and *C. glabrata*), one genus and species from each *Saccharomyces cerevisiae*, and *Rhodotoryoa rubra* by disc diffusion method.

Materials and Methods: Sputum was taken from 30 patients with malignant disease, different micro and macroscopical tests were used to identified the 14 isolated fungi from them 1 genus from mold of *Aspergillus*, and 3 genus from yeast, from genus *Aspergillus* 3 species recognized as tailed, *A. flavus*, *A. niger*, and *A. fumigatus*. On the other hand from yeast of genus *Candida*, *C. albicans* and *C. glabrata*, whereas from genus *Saccharomyces*, and *Rhodotoula*, *Saccharomyces cerevisiae* and *Rhodotoula rubra* were recognized.

Results: Antimycotic susceptibility test exhibited zone of inhibition against yeast ranged from (30-20), (30-15), (30-15), and (25-15) against *C. albicans*, *C. glabrata* *Saccharomyces cerevisiae* and *Rhodotoula rubra* respectively, while mold show zone of inhibition ranged from (25-10), (10-0), and (30-10) against *A. flavus*, *A. niger*, and *A. fumigatus* respectively, although rosuvastatin show an antifungal activity only at dose 0.6 mg/ml against *A. niger*.

Conclusion: Rosuvastatin has antifungal activity apart of its pleiotropic activity of statins.

Keywords: Mold, Rosuvastatin, Yeast, Zone of inhibition.

النشاط المضاد للفطريات للرسوفاستاتين

الخلاصة:

المدخل: تعد الزيادة الطردية في مقاومة الميكروبات مشكلة صحية عالمية نتيجة للاستخدام غير المنضبط للأدوية المضادة للميكروبات، ومن أجل التغلب على هذا التحدي، هناك حاجة مستمرة للبحث عن مضادات جديدة للميكروبات إما عن طريق التحقيق في مركبات جديدة أو إعادة استخدام الأدوية، أي تحديد سريري جديد. باستخدام العامل المعتمد الحالي وبالتالي يؤدي إلى توفير في الوقت والتكلفة اللازمين لتطوير علاج جديد مضاد للميكروبات

الهدف: هدفت هذه الدراسة إلى تقييم النشاط المضاد للفطريات خارج جسم الانسان لتراكيز مختلفة من رسوفاستاتين على 4 فطريات معزولة من مرضى مصابين بأورام خبيثة منهم 1 من جنس العفنيات، من 3 أنواع وهي (*A. flavus*، *A. niger*، *A. fumigatus*) و 3 اجناس من الخميرة من جنس المبيضات من نوعين (*C. albicans* و *C. glabrata*)، و جنس واحد ونوع واحد من كل *Rhodotoryoa rubra* و *Saccharomyces cerevisiae* بطريقة الانتشار بالقرص والطبق.

المواد وطرق العمل: تم أخذ البلغم من 30 مريضاً يعانون من مرض خبيث ، واستخدمت اختبارات عينية وميكروسكوبية مختلفة للتعرف على 14 نوعاً من الفطريات المعزولة منهم ، جنس واحد من العفنيات ، و 3 جنس من الخميرة ، من جنس العفنيات تم تشخيص 3 أنواع وهي ، *A. flavus* ، *A. niger* ، و *A. fumigatus*. من ناحية أخرى تم التعرف على الخميرة من جنس المبيضات ، *C. glabrata* ، *C. albicans* ، بينما من جنس *Saccharomyces* و *Rhodotoula* ، تم التعرف على *Rhodotoula rubra* و *Saccharomyces cerevisiae*.
النتائج: أظهر اختبار الحساسية لمضادات الفطريات أن منطقة التثبيط ضد الخمائر تراوحت بين (20-30) ، (15-30) ، (30-15) ، (15-25) ، (25-15) ضد *Rhodotoula rubra* و *Saccharomyces cerevisiae* ، *C. glabrata* ، *C. albicans* على التوالي ، بينما تظهر منطقة التثبيط للعفن بين (10-25) ، (0-10) ، (10-30) ضد *A. flavus* ، *A. niger* ، و *A. fumigatus* على التوالي ، على الرغم من أن الرسوفاستاتين يظهر نشاط مضاد للفطريات فقط عند تناول جرعة 0.6 ملغ / مل ضد *A. niger*.
الملخص: يحتوي رسوفاستاتين على نشاط مضاد للفطريات بصرف النظر عن النشاط المتعدد الاتجاهات للسستاتينات.

الكلمات المفتاحية: عفنيات, رسوفاستاتين, خمائر, منطقة التثبيط.

INTRODUCTION

Today's a steady increase in microbial resistance is a global health problem as a result of uncontrolled use of antimicrobial drugs, thus the trend nowadays is to use an alternative measures of repurposing drugs to find other indications of an approved non antibiotic drugs. searching for drugs with antimicrobial activity is approach pharmaceutical companies in order to save time and cost required to develop a new antimicrobial therapy (1).

Rosuvastatin is one of the most commonly used of statin group, it act as compelling 3-hydroxy-3-methylglutaryl-CoenzymeA (HMG)-CoA reductase inhibitors, In addition, rosuvastatin possess a pleiotropic activity unconnected to its lipid lowering effect, latest studies implies the diverse extrahepatic pharmacological activities allied with statins class, especially rosuvastatin, such off target effect include antioxidant activity, increase in cytokines concentration, impede some markers associated with inflammation, which owing to inhibit biosynthesis of imperative isoprenoid intermediates then tracked by reduction in

signaling molecules similar to Rho, Ras, and Rac (2,3).

Moreover, Rosuvastatin have been shown to assess antibacterial and antifungal action, diverse theories have been suggested regarding its antimicrobial mechanism of action however, the most conventional one related to the being there of pyrimidine ring in rosuvastatin structures, in addition to its pleiotropic activity which is promising and several effects are being speculated (4).

Fungal infection was the furthestmost mutual cause of morbidity and mortality especially in cancer patients, the most isolated fungi from such patients was yeast frequently from genus *Candida*, tracked by *Aspergillus*, then rare fungi, the most mutual encountered species from genus *Candida* was *Candida albicans*, *Candida glabrata*, *Candida krusei*, and *Candida parapsilosis*, in the other hand the most mutual isolated species of genus *Aspergillus* was, *A. flavus*, *A. niger*, *A. fumigatus* and *A. terreus* (5). Fungal resistance have a clinical implication which conduct a surveillance that led to heightened interest in the study of antifungal resistance from different angles and search for new class of existing drugs with antifungal potential(6).

Furthermore, researcher shift the way toward the non -antimicrobial medications with various pharmacological activity, epidemiological results highlighted that individuals using statins are less in danger to bacterial and fungal infection (7). Also a countless *in vivo* and *in vitro* studies identified the antibacterial and antifungal activity of statin.

Accordingly, the aim of the present study was to assess *in vitro* antimycotic activity to different concentrations of rosuvastatin in contrast to isolated 4 fungi from patients with malignancies from them 1 mold of genus *Aspergillus*, of 3 species (*A. flavus*, *A.niger*, and *A. fumigatus*) and 3 yeast of genus *Candida* of 2 species (*C. albicans* , and *C. glabrata*), one genus and species from each *Saccharomyces cerevisiae* , and *Rhodotoriya rubra* by disc diffusion method.

MATERIALS and METHODS

Patients

Thirty patients with malignant disease were included in this study. They were attending out patients clinics (from March –May 2022) with sign and symptoms of chest infection, Sputum was collected. microbiology laboratory testing for isolation and identification.

Isolation and identification

Sputum was inspected by direct microscopical investigation by Gram stain for presence of any conidial head morphology for mold or budding cell for yeast, on the other hand sputum was cultured on double plate of cezpek's agar for mold investigation, double plates of Brain- Heart

infusion blood agar supplemented with chloramphenicol was used for yeast. The inoculated plates for mold incubated for 5-7 days at 28-30 °C, however plates for yeast incubated for 2-3 days at 37°C. One genus of mold were identified by macroscopical inspected by perceive their colony morphology by distinguish their pigmentation, wooly and velvety, On the other hand, microscopical inspection by mixing portion of mold colony with lactophenol mount and examine under 40X light microscope, one genus of *Aspergillus* of three species that include *A.flavus*, *A.niger*, and *A.fumigatus* were identified (8, 9).

Although yeast colony inspected macroscopically by existence of colored pasty colony, while microscopical inspected by mixing portion of the colony with Gram stain and inspected under 100X light microscope for presence of budding yeast cell, however from yeast 3 genus were identified which include *Candida*, *Saccharomyces*, and *Rhodotorula*. From genus *Candida* 2 species were recognized *C. albicans*, and *C. glabrata*, however *C. albicans* was identified by germ tube test, and chlamydospre positive test, while *C.glabrata* was identified by API C 10 system. *Saccharomyces cerevisiae* and *Rhodotorula rubra* were recognized from genus *Saccharomyces* and *Rhodotorulla*, by colony morphology and lactophenol mount. After uniqueness the isolates were reserved in stock bottle culture for later use in susceptibility test (10,11).

This study intended to detect the antimycotic activity of rosuvastatin in contrast to isolated mold and yeast. In this study Rosuvastatin

tablet 20mg/day (Crestor, AstraZeneca) obtained from local pharmacy was used.

Susceptibility test

Muller-Hinton agar was used to assess the antimycotic activity of rosuvastatin by disc diffusion method, inoculum from every stock isolate was prepared in concentration equal to 0.5 McFarland (1.5×10^8 CFU/ml). Stock solution of rosuvastatin was prepared by dissolving rosuvastatin (2.5 mg) in 1ml of 1% DMSO (dimethyl sulfoxide) then serial dilution to accomplish the following concentration (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 mg/ml) (12, 13).

In vitro antifungal activity

One hundred filter papers in 6 mm diameter were soaked in each concentration of rosuvastatin solution for overnight, then each tested fungal isolate was spread uniformly on the surface of Muller-Hinton agar by sterile cotton swab, discs of rosuvastatin in different concentration was placed on the surface of sensitivity medium, in addition to fluconazole disc (50ug/disc) by sterile

forceps as a control. Inoculated plates incubated at 37 °C, then the mean diameter of inhibition zone were measured as a clear zone around the disc after 24,48 and 72 hr. sensitivity test was repeated in triplicate for each isolate to ensure the accuracy of the technique, fluconazole disc use as a positive control, however DMSO use as a solvent control DMSO with this concentration has no antifungal activity (14).

RESULTS

From thirty malignant patients with chest infection, 14 isolated fungi were identified, from them 5 isolates from mold and 9 isolate from yeast, from mold one genus of *Aspergillus* were isolated from them 3 species, there were 3 from *A. flavus*, and 1 from each *A. niger* and *A. fumigatus*. While from yeast three genus were isolated from them 7 from genus *Candida* there were 6 from *C. albicans* and 1 from *C. glabrata* in addition to 1 isolate from each *Saccharomyces cerevisiae* and *Rhodotorula rubra* as shown in Table 1 and Table 2.

Table 1. Number of isolated mold from malignant patients.

Mold	No. of isolate
<i>Aspergillus flavus</i>	3
<i>Aspergillus niger</i>	1
<i>Aspergillus fumigatus</i>	1

Table 2. Number of isolated yeast from malignant patients.

Yeast	No. of isolate
<i>Candida albicans</i>	6

<i>Candida glabrata</i>	1
<i>Saccharomyces cerevisiae</i>	1
<i>Rhodotoryoa rubra</i>	1

In this study, the antifungal activity of rosuvastatin was tested against the recognized isolates of mold and yeast, from the result of inhibition zone as shown in Table3, Table4, and Figure 1, Figure 2 , the maximum activity of rosuvastatin was detected with the highest concentration of

0.6 mg /ml concentration the inhibition zone decrease with manner of concentration thus the effect of rosuvastatin is concentration-dependent, In addition, the results of inhibition zone showed that the antifungal activity of rosuvastatin against yeast was higher than mold.

Table3. Antifungal activity of rosuvastatin in relation to zone of inhibition against mold.

Fungi	Rosuvastatin concentration disc in mg/ml					
	0.6	0.5	0.4	0.3	0.2	0.1
	Mean zone of inhibition in mm					
<i>A. flavus</i>	25	25	25	20	20	10
<i>A. niger</i>	10	0	0	0	0	0
<i>A. Fumigatus</i>	30	30	25	25	25	10

Table4. Antifungal activity of rosuvastatin in relation to zone of inhibition against yeast.

Fungi	Rosuvastatin concentration disc in mg/ml					
	0.6	0.5	0.4	0.3	0.2	0.1
	Mean zone of inhibition in mm					
<i>C. albicans</i>	30	30	25	25	20	20
<i>C. glabrata</i>	30	25	25	20	20	15
<i>R. rubra</i>	30	30	25	25	15	15
<i>S. cerevisiae</i>	25	25	20	20	15	15

*A.flavus**A.niger**A. fumigatus***Figure 1.** The antifungal activity of rosuvastatin against mold.*C.albicans**C.glabrata**R.rubra**S.cerevisiae***Figure 2.** The antifungal activity of rosuvastatin against yeast.

DISCUSSION

Fungi class containing various members. Antifungal resistance is an inclusive issues of countless health problem in different, The resistance to antifungal drugs was recorded especially in immunocompromised patients which shift the way to discover the antimicrobial activity in the existing drugs, many studies designed for detection a new antibiotic class of drug sources, so that certain non- antibiotic with antimicrobial therapy could be used as a supportive or in combination with antifungal drugs (15).

In this study *Candida* spp. then followed by *Aspergillus* species, then rare fungi of each

Saccharomyces cerevisiae and *Rhodotorula rubra* were the foremost isolated fungi from patients with malignancies. Fungal infection inspection among cancer patients to *Candida* species, then followed by *Apergillus* species with variance in frequency rendering to the countries (16).

Researchers noticed that patients on statin containing drugs for lipid lowering remedy had a lower risk to get fungemia or even septicemia this antimicrobial activity could be attributed to the pleiotropic influence of statins (17).

The result of the current study which was designed to examine the antimycotic activity

of rosuvastatin against isolated fungi 1 of them were mold and 3 yeast by using disc diffusion method. All the isolated yeast and mold showed zone of inhibition at the highest concentration of rosuvastatin at 0.6 mg/ml. the inhibition zone was decreasing in dose dependent manner.

Rendering to inhibition zone of rosuvastatin which exert a powerful antifungal activity at all concentration against genus *Aspergillus* of species *A. fumigatus* and *A. flavus*, However, rosuvastatin show an antifungal activity only at dose 0.6 mg/ml in contrast to *A. niger*.

Similarly, rosuvastatin has antifungal activity in all concentration against yeast that include *Candida* spp., *Saccharomyces cerevisiae*, and *Rhodotoryoa rubra*.

Although the Antifungal activity of rosuvastatin still poorly understood with respect to its antimicrobial mechanism, It is quite possible that antifungal activity to be connected with its ability to inhibit synthesis of isoprenoids, which affect several important biosynthesis of ergosterol, the inhibition in turn result in modulation of G-protein actions, and activation of Ras and Ras-like signaling, the latter result in destruction of fungal cell wall, and reduction of new fungal cell formation (18).

Galgoczy and Coworkers (2011) (19) studied the intrinsic activity of rosuvastatin as antifungal medication on *Candida albicans*, *Candida glabrata*, *Candida krusei*, *Aspergillus flavus* and *Aspergillus fumigatus* their results showed that rosuvastatin inhibitory dose ranged from 0.25 - 23 µg/ml. On the other hand, Jayalekshmi and Coworkers (2020) (20) showed that the

forceful antifungal inhibitory concentration of rosuvastatin against yeast was 128 µg/ml, and 8 µg/ml against mold (2). However, rosuvastatin assess an extensive spectrum of antifungal activity against (*Candida* spp., *Aspergillus* spp., *Saccharomyces cerevisiae*, and *Dermatophytes*), in addition to boost the activity of antifungal medications (2,122).

CONCLUSION

In summary, this study concluded that rosuvastatin possess a good antimycotic activity against different genus of isolated fungal species, which documented by suppress the fungal growth by susceptibility disc diffusion method, the result of the current study augmented the antifungal activity of rosuvastatin. more studies showed be done to examine the effects of other statin members on fungal growth and to explore the molecular mechanism of this inhibition.

ACKNOWLEDGEMENT

The author is grateful to acknowledge the College of Pharmacy – University of Mosul for providing the necessary facilities to carry out this study.

CONFLICT OF INTEREST: no conflict of interest.

REFERENCES

1. Parsamanesh N, Karami-Zarandi M, Banach M, Penson PE, Sahebkar A. Effects of statins on myocarditis: a review of underlying molecular mechanisms. Progress in cardiovascular diseases. 2021;67:53-64.
2. Lima WG, Alves-Nascimento LA, Andrade JT and Vieira L: Are the statins promising antifungal agents against invasive

- candidiase. *Biomed Pharmacother* 2019; 3(111): 270-281.
3. Zhang Y, Chen Z, Wen Q, Xiong Z, Cao X, Zheng Z, Zhang Y, Huang Z. An overview on the biosynthesis and metabolic regulation of monacolin K/lovastatin. *Food & function*. 2020;11(7):5738-5748.
 4. Welsh AM, Kruger P, Faoagali J. Antimicrobial action of atorvastatin and rosuvastatin. *Pathology*. 2009;41(7):689-691.
 5. El-Mahallawy HA, Attia I, Ali-el-Din NH, Salem AE, Abo-el-Naga S. A prospective study on fungal infection in children with cancer. *Journal of medical microbiology*. 2002;51(7):601-73.
 6. Baddley JW, Moser SA. Emerging fungal resistance. *Clinics in laboratory medicine*. 2004;24(3):721-35.
 7. Vadivoo VS, Dhinkar RG and Balasubramanian S: Elucidation of possible antibacterial effects of statins against primary pathogens of mastitis in cows. *The Pharma Innovation Journal*. 2018; 7(12): 30-33.
 8. Greub G, Bille J. *Aspergillus* species isolated from clinical specimens: suggested clinical and microbiological criteria to determine significance. *Clinical microbiology and infection*. 1998;4(12):710-6.
 9. Mailafia S, Olabode HO, Osanupin R. Isolation and identification of fungi associated with spoiled fruits vended in Gwagwalada market, Abuja, Nigeria. *Veterinary world*. 2017 ;10(4):393.
 10. Larone DH, Larone DH. *Medically important fungi: a guide to identification*. New York: Elsevier; 1987.
 11. Shokri H, Khosravi A, Sharifzadeh A, Tootian Z. Isolation and identification of yeast flora from genital tract in healthy female camels (*Camelus dromedarius*). *Veterinary microbiology*. 2010;144(1-2):183-6.
 12. Pehlivanović B, Čaklović K, Lagumdžija D, Žiga Smajić N, Bečić F. In-vitro evaluation of pleiotropic properties of rosuvastatin. *Int. J. Pharm. Sci. Res*. 2021;12(2):1000-6.
 13. Pottz GE, Rampey JH, Benjamin F. The effect of dimethyl sulfoxide (DMSO) on antibiotic sensitivity of a group of medically important microorganisms: preliminary report. *Ann N Y Acad Sci*. 1967;141(1):261-272.
 14. Qiao J, Kontoyiannis DP, Wan Z, Li R, Liu W. Antifungal activity of statins against *Aspergillus* species. *Medical mycology*. 2007;45(7):589-93.
 15. Pereira NL, Aquino PE, Júnior JG, Cristo JS, Vieira Filho MA and Moura FF: Antibacterial activity and antibiotic modulating potential of the essential oil obtained from *Eugenia jambolana* in association with led lights. *J Photochem Photobiol B* 2017; 174: 144-149.
 16. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, Naoe S. Fungal infections in cancer patients: an international autopsy survey. *European Journal of Clinical Microbiology and Infectious Diseases*. 1992;11(2):99-109.
 17. Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadily AK. Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study. *Journal of laboratory physicians*. 2018;10(03):271-5.

18. Silva RR, Shrestha-Bajracharya D, Almeida-Leite CM, Leite R, Bahia MT, Talvani A. Short-term therapy with simvastatin reduces inflammatory mediators and heart inflammation during the acute phase of experimental Chagas disease. *Memórias do Instituto Oswaldo Cruz.* 2012;107:513-21.
19. Galgóczy, L.N., Nyilasi, I., Papp, T. and Vágvölgyi, C., (2011). Statins as antifungal agents. *World Journal of Clinical Infectious Diseases.* 2011; 1(1), 4-10.
20. Jayalekshmi SK, Antony TM, Ramasamy S. Elucidation of Antifungal, Antioxidant and Anticholesterol Activity of Efficiency of Fungal Statin Isolated from *Aspergillus tamarii*. *Biosc Biotech Res Comm.* 2020; 13 (3) :1597-1604.
21. Tavakkoli A, Johnston TP, Sahebkar A. Antifungal effects of statins. *Pharmacology & Therapeutics.* 2020;208:107483.
22. Hashim ZA. Evaluation of bacterial contents, package labelling and antimicrobial activity of some commercial probiotic products available in local market. *Journal of research in pharmacy.* 2022;26(3):502-509.